Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01649791 · ClinicalTrials.gov registry record · NA
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
A NA study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01649791: Clinical Trial NA study, sponsored by Roswell Park Cancer Institute.
NCT01649791 is a NA study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01649791, a NA study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This clinical trial studies lenalidomide as chemoprevention in treating patients with high-risk, early stage B-cell chronic lymphocytic leukemia (B-CLL). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of lenalidomide may slow disease progression in patients with early stage B-cell chronic lymphocytic leukemia
Interventions
- OTHER laboratory biomarker analysis
- DRUG lenalidomide
- OTHER pharmacological study
- PROCEDURE bone marrow aspiration
- PROCEDURE lymph node biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-10 |
| Phase | NA |
Why NCT01649791 stopped before completion
NCT01649791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01649791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01649791 about?
NCT01649791 is a clinical study titled "Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia". This clinical trial studies lenalidomide as chemoprevention in treating patients with high-risk, early stage B-cell chronic lymphocytic leukemia (B-CLL). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of lenalidomide may slow disease progression in patients with ear...
What is the current status of trial NCT01649791?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2010-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01649791?
The interventions under investigation include: laboratory biomarker analysis (OTHER), lenalidomide (DRUG), pharmacological study (OTHER), bone marrow aspiration (PROCEDURE), lymph node biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01649791?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01649791's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia